Drag a card by its title · ⚙ to size, swap or remove

The company

NewAmsterdam Pharma Company N.V. -

NAMS · Nasdaq

Health CareBiotechnologyNot moving yet

NAMS stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 21 weeks. It is 30.6% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 21
Industry in uptrend: 16% -15 in 4 wk
Insider buys, 12 months: $453K
Insider sales, 12 months: $120.1M
Officials’ trades on record: 0
Institutions holding: 187 (+22)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

20 Apr – 19 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months29

Buyers · sellers1 · 6

Who	Did	Shares	Traded
Johannes Jacob Pieter KasteleinChief Scientific Officer	sold	50,246at $25.03	30 Sep 2026filed 2 Oct 2026
Michael H. DavidsonChief Executive Officer	bought	10,000at $22.65	14 Sep 2026filed 15 Sep 2026
John W. SmitherDirector	sold	1,600at $25.32	4 Sep 2026filed 9 Sep 2026
Johannes Jacob Pieter KasteleinChief Scientific Officer	sold	125,000at $26.91	24 Aug 2026filed 25 Aug 2026
Louise Frederika KooijChief Accounting Officer	sold	70,200at $29.96	20 Jul 2026filed 22 Jul 2026
Louise Frederika KooijChief Accounting Officer	sold	31,885at $31.05	20 Jul 2026filed 22 Jul 2026
Louise Frederika KooijChief Accounting Officer	sold	2,915at $31.71	20 Jul 2026filed 22 Jul 2026
Louise Frederika KooijChief Accounting Officer	sold	39,700at $30.20	22 Jun 2026filed 24 Jun 2026
Louise Frederika KooijChief Accounting Officer	sold	300at $30.73	22 Jun 2026filed 24 Jun 2026
Louise Frederika KooijChief Accounting Officer	sold	65,000at $35.69	26 May 2026filed 27 May 2026
Louis G. LangeDirector	sold	44,173at $30.41	11 Mar 2026filed 12 Mar 2026
Louis G. LangeDirector	sold	446at $31.23	11 Mar 2026filed 12 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders187+22 on the quarter

New · exited46 · 23

Reported value$3.9B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Frazier Life Sciences Management, L.P.added · filed 14 Aug 2026	18,088,902$613.0M	+1,145,128+6.8%
Capital World Investorsadded · filed 12 Aug 2026	12,230,557$414.5M	+1,121,523+10.1%
FMR LLCadded · filed 13 Aug 2026	10,339,663$350.4M	+1,573,852+18.0%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026	9,550,191$323.7M	00.0%
FCPM III SERVICES B.V.reduced · filed 14 Aug 2026	8,490,353$287.7M	-708,547−7.7%
DEERFIELD MANAGEMENT COMPANY, L.P.unchanged · filed 14 Aug 2026	4,264,789$144.5M	00.0%
VIKING GLOBAL INVESTORS LPunchanged · filed 14 Aug 2026	4,203,567$142.5M	00.0%
Bain Capital Life Sciences Investors, LLCreduced · filed 14 Aug 2026	3,806,566$129.0M	-3,500,000−47.9%
MAVERICK CAPITAL LTDadded · filed 14 Aug 2026	3,267,802$110.7M	+1,081,400+49.5%
Jupiter Topco LLCnew · filed 14 Aug 2026	2,535,682$86.0M	+2,535,682